Stemgent Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Stemgent Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013245
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Stemgent Inc (Stemgent), a part of the ReproCELL Group is a biotechnology company that focuses on the development of innovative technology and application solutions for the advancement of stem cell research. The company’s product portfolio comprises antibodies, cell lines, cytokines / proteins, differentiation, matrices, media, reprogramming systems, small molecules and transfection. It also offers iPS cell services and training courses for research scholars of various research laboratories. These training courses cover all essential protocols for lentiviral and mRNA reprogramming and human induced pluripotent (iPS) cell culture techniques in a hands-on laboratory environment. The company operates research sites in Cambridge, Massachusetts and San Diego, California. Stemgent is headquartered in Cambridge, Massachusetts, the US.

Stemgent Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Stemgent Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Stemgent Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Stemgent Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Stemgent Inc, Medical Devices Deals, 2011 to YTD 2017 8
Stemgent Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Stemgent Inc, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Stemgent Completes Acquisition Of Human Tissue Business From Asterand For US$9 Million 10
Venture Financing 12
Stemgent Raises US$11.3 Million In Venture Financing 12
Stemgent Raises US$6.3 Million In Series C Financing 13
Stemgent Secures US$0.58 Million In Venture Financing 14
Stemgent Secures US$0.75 Million In Venture Financing 15
Partnerships 16
ATCC Enters Into Co-Development Agreement With Stemgent 16
Licensing Agreements 17
Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 17
Asset Transactions 18
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 18
Stemgent Inc – Key Competitors 19
Stemgent Inc – Key Employees 20
Stemgent Inc – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Stemgent Inc, Pharmaceuticals & Healthcare, Key Facts 2
Stemgent Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Stemgent Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Stemgent Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Stemgent Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Stemgent Inc, Medical Devices Deals, 2011 to YTD 2017 8
Stemgent Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Stemgent Completes Acquisition Of Human Tissue Business From Asterand For US$9 Million 10
Stemgent Raises US$11.3 Million In Venture Financing 12
Stemgent Raises US$6.3 Million In Series C Financing 13
Stemgent Secures US$0.58 Million In Venture Financing 14
Stemgent Secures US$0.75 Million In Venture Financing 15
ATCC Enters Into Co-Development Agreement With Stemgent 16
Stemgent Enters Into Licensing Agreement With iPS Academia For Induced Pluripotent Stem Cell Patent Portfolio 17
ReproCELL Acquires Induced Pluripotent Stem Cell Business from Stemgent for USD8.5 Million 18
Stemgent Inc, Key Competitors 19
Stemgent Inc, Key Employees 20
Stemgent Inc, Other Locations 21

★海外企業調査レポート[Stemgent Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kalle GmbH:企業の戦略的SWOT分析
    Kalle GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Dunelm Group plc (DNLM):企業の財務・戦略的SWOT分析
    Dunelm Group plc (DNLM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Dr. Ci:Labo Co., Ltd.:企業の戦略・SWOT・財務情報
    Dr. Ci:Labo Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Dr. Ci:Labo Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Lego AS:企業の戦略的SWOT分析
    Lego AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Polpharma SA:企業の戦略的SWOT分析
    Polpharma SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Cognition Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Cognition Therapeutics Inc (CogRx) is a drug discovery and development company that discovers and develops small molecule therapeutics to improve the lives of individuals with Alzheimer’s disease and other neurocognitive disorders. The company uses its proprietary biology and chemistry platf …
  • Amedisys Inc (AMED)-製薬・医療分野:企業M&A・提携分析
    Summary Amedisys Inc (Amedisys) is a healthcare company that offers home health care, hospice service and personal care. The company provides practical nursing services and occupational therapy, comfort and support services for those are facing a terminal illness. It also provides speech pathology, …
  • Cytogel Pharma LLC-製薬・医療分野:企業M&A・提携分析
    Summary Cytogel Pharma LLC (Cytogel Pharma) is a biopharmaceutical development company that provides platform technologies and product candidates. The company offers novel analgesic product candidates and polymer and hydrogel drug delivery platform technologies. Its analgesic product candidates offe …
  • OncoResponse Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary OncoResponse Inc (OncoResponse) focuses on the discovery, development and commercialization of therapeutic antibodies for the treatment of cancer. The company’s lead program includes ONCR-201, an anti-EMP2 fully-human monoclonal antibody, which is developed for female malignancies. It utiliz …
  • Shri Lakshmi Defence Solutions Ltd.:企業の戦略・SWOT・財務情報
    Shri Lakshmi Defence Solutions Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shri Lakshmi Defence Solutions Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • General Re Corporation:企業の戦略的SWOT分析
    General Re Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • RPP Infra Projects Ltd (RPPINFRA):企業の財務・戦略的SWOT分析
    RPP Infra Projects Ltd (RPPINFRA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Doosan Heavy Industries & Construction Co Ltd (034020):企業の財務・戦略的SWOT分析
    Doosan Heavy Industries & Construction Co Ltd (034020) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s …
  • H.I.S. Co., Ltd.:企業の戦略・SWOT・財務情報
    H.I.S. Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary H.I.S. Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Mutuelle Generale de l’Education Nationale:企業の戦略的SWOT分析
    Mutuelle Generale de l'Education Nationale - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • JGC Corp (1963):電力:M&Aディール及び事業提携情報
    Summary JGC Corp (JGC) is an engineering contracting company. It offers engineering, procurement and construction services for various engineering contracts and projects in the areas of oil and gas development, petroleum refining, natural gas processing, petrochemicals, clean energy and power genera …
  • Canbriam Energy Inc:石油・ガス:M&Aディール及び事業提携情報
    Summary Canbriam Energy Inc (Canbriam) is an oil and gas exploration company that offers finding and developing liquids rich natural gas resources. The company develops liquids rich natural gas resources in the Western Canadian Sedimentary Basin. It owns and operates oil and gas producing properties …
  • TDK Corporation (6762):企業の財務・戦略的SWOT分析
    TDK Corporation (6762) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • National Heart Lung and Blood Institute-製薬・医療分野:企業M&A・提携分析
    Summary National Heart Lung and Blood Institute (NHLBI), a subsidiary of National Institutes of Health is a medical research institute that provides treatment for heart, lung, and blood diseases.The institute conducts research studies with patients who have diseases of heart and blood vessels, lungs …
  • Gould Paper Corporation, Inc.:企業の戦略・SWOT・財務情報
    Gould Paper Corporation, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gould Paper Corporation, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆